ID   DHB8_HUMAN              Reviewed;         261 AA.
AC   Q92506; A6NLX7; Q5STP7; Q9UIQ1;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2001, sequence version 2.
DT   10-MAY-2017, entry version 170.
DE   RecName: Full=Estradiol 17-beta-dehydrogenase 8;
DE            EC=1.1.1.62 {ECO:0000269|PubMed:17978863};
DE   AltName: Full=17-beta-hydroxysteroid dehydrogenase 8 {ECO:0000303|PubMed:17978863};
DE            Short=17-beta-HSD 8;
DE   AltName: Full=3-ketoacyl-[acyl-carrier-protein] reductase alpha subunit {ECO:0000303|PubMed:25203508};
DE            Short=KAR alpha subunit {ECO:0000303|PubMed:25203508};
DE   AltName: Full=3-oxoacyl-[acyl-carrier-protein] reductase;
DE            EC=1.1.1.- {ECO:0000269|PubMed:19571038, ECO:0000269|PubMed:25203508};
DE   AltName: Full=Protein Ke6;
DE            Short=Ke-6;
DE   AltName: Full=Really interesting new gene 2 protein;
DE   AltName: Full=Short chain dehydrogenase/reductase family 30C member 1;
DE   AltName: Full=Testosterone 17-beta-dehydrogenase 8;
DE            EC=1.1.1.239;
GN   Name=HSD17B8; Synonyms=FABGL, HKE6, RING2, SDR30C1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3-261.
RX   PubMed=8812499; DOI=10.1006/geno.1996.0405;
RA   Ando A., Kikuti Y.Y., Shigenari A., Kawata H., Okamoto N., Shiina T.,
RA   Chen L., Ikemura T., Abe K., Kimura M., Inoko H.;
RT   "cDNA cloning of the human homologues of the mouse Ke4 and Ke6 genes
RT   at the centromeric end of the human MHC region.";
RL   Genomics 35:600-602(1996).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND TISSUE SPECIFICITY.
RX   PubMed=17978863; DOI=10.1007/s11010-007-9637-9;
RA   Ohno S., Nishikawa K., Honda Y., Nakajin S.;
RT   "Expression in E. coli and tissue distribution of the human homologue
RT   of the mouse Ke 6 gene, 17beta-hydroxysteroid dehydrogenase type 8.";
RL   Mol. Cell. Biochem. 309:209-215(2008).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CBR4.
RX   PubMed=19571038; DOI=10.1096/fj.09-133587;
RA   Chen Z., Kastaniotis A.J., Miinalainen I.J., Rajaram V.,
RA   Wierenga R.K., Hiltunen J.K.;
RT   "17beta-Hydroxysteroid dehydrogenase type 8 and carbonyl reductase
RT   type 4 assemble as a ketoacyl reductase of human mitochondrial FAS.";
RL   FASEB J. 23:3682-3691(2009).
RN   [8]
RP   INDUCTION BY ESTRADIOL.
RX   PubMed=18852215; DOI=10.1677/JOE-08-0134;
RA   Rotinen M., Celay J., Alonso M.M., Arrazola A., Encio I., Villar J.;
RT   "Estradiol induces type 8 17beta-hydroxysteroid dehydrogenase
RT   expression: crosstalk between estrogen receptor alpha and C/EBPbeta.";
RL   J. Endocrinol. 200:85-92(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 6-261 IN COMPLEX WITH NAD.
RG   Structural genomics consortium (SGC);
RT   "Structure of human hydroxysteroid dehydrogenase type 8, HSD17B8.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [12] {ECO:0000244|PDB:4CQL, ECO:0000244|PDB:4CQM}
RP   X-RAY CRYSTALLOGRAPHY (2.34 ANGSTROMS) IN COMPLEX WITH NAD AND CBR4,
RP   SUBUNIT, FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND MUTAGENESIS OF
RP   ASP-42; ARG-148; TYR-169; LYS-173 AND ARG-189.
RX   PubMed=25203508; DOI=10.1038/ncomms5805;
RA   Venkatesan R., Sah-Teli S.K., Awoniyi L.O., Jiang G., Prus P.,
RA   Kastaniotis A.J., Hiltunen J.K., Wierenga R.K., Chen Z.;
RT   "Insights into mitochondrial fatty acid synthesis from the structure
RT   of heterotetrameric 3-ketoacyl-ACP reductase/3R-hydroxyacyl-CoA
RT   dehydrogenase.";
RL   Nat. Commun. 5:4805-4805(2014).
RN   [13]
RP   VARIANT [LARGE SCALE ANALYSIS] LEU-158.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: NAD-dependent 17-beta-hydroxysteroid dehydrogenase with
CC       highest activity towards estradiol. Has very low activity towards
CC       testosterone (PubMed:17978863). The heterotetramer with CBR4 has
CC       NADH-dependent 3-ketoacyl-acyl carrier protein reductase activity,
CC       and thereby plays a role in mitochondrial fatty acid biosynthesis
CC       (PubMed:19571038, PubMed:25203508). Within the heterotetramer,
CC       HSD17B8 binds NADH; CBR4 binds NADPD (PubMed:25203508).
CC       {ECO:0000269|PubMed:17978863, ECO:0000269|PubMed:19571038,
CC       ECO:0000269|PubMed:25203508}.
CC   -!- CATALYTIC ACTIVITY: 17-beta-estradiol + NAD(P)(+) = estrone +
CC       NAD(P)H. {ECO:0000269|PubMed:17978863}.
CC   -!- CATALYTIC ACTIVITY: Testosterone + NAD(+) = androstenedione +
CC       NADH. {ECO:0000269|PubMed:17978863}.
CC   -!- PATHWAY: Steroid biosynthesis; estrogen biosynthesis.
CC       {ECO:0000269|PubMed:17978863}.
CC   -!- PATHWAY: Lipid metabolism; fatty acid biosynthesis.
CC       {ECO:0000269|PubMed:25203508}.
CC   -!- SUBUNIT: Heterotetramer with CBR4; contains two molecules of
CC       HSD17B8 and CBR4. {ECO:0000269|PubMed:25203508,
CC       ECO:0000269|Ref.11}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix
CC       {ECO:0000269|PubMed:19571038}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in placenta, liver and
CC       pancreas, lower in the skeletal muscle and kidney. Widely
CC       expressed. {ECO:0000269|PubMed:17978863}.
CC   -!- INDUCTION: Up-regulated by estradiol.
CC       {ECO:0000269|PubMed:18852215}.
CC   -!- SIMILARITY: Belongs to the short-chain dehydrogenases/reductases
CC       (SDR) family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BT007239; AAP35903.1; -; mRNA.
DR   EMBL; AL031228; CAC38444.1; -; Genomic_DNA.
DR   EMBL; AL662824; CAI17616.1; -; Genomic_DNA.
DR   EMBL; AL713971; CAI17616.1; JOINED; Genomic_DNA.
DR   EMBL; AL713971; CAI17657.1; -; Genomic_DNA.
DR   EMBL; AL662824; CAI17657.1; JOINED; Genomic_DNA.
DR   EMBL; AL645940; CAI18068.1; -; Genomic_DNA.
DR   EMBL; AL844527; CAI41840.1; -; Genomic_DNA.
DR   EMBL; CR759786; CAQ08245.1; -; Genomic_DNA.
DR   EMBL; CR759733; CAQ10302.1; -; Genomic_DNA.
DR   EMBL; CR847841; CAQ10313.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03682.1; -; Genomic_DNA.
DR   EMBL; BC008185; AAH08185.1; -; mRNA.
DR   EMBL; D82061; BAA11529.1; -; mRNA.
DR   CCDS; CCDS4769.1; -.
DR   RefSeq; NP_055049.1; NM_014234.4.
DR   UniGene; Hs.415058; -.
DR   PDB; 2PD6; X-ray; 2.00 A; A/B/C/D=6-261.
DR   PDB; 4CQL; X-ray; 2.85 A; A/D/E/H/I/L/M/P=1-261.
DR   PDB; 4CQM; X-ray; 2.34 A; A/D/E/H/I/L/M/P=1-261.
DR   PDBsum; 2PD6; -.
DR   PDBsum; 4CQL; -.
DR   PDBsum; 4CQM; -.
DR   ProteinModelPortal; Q92506; -.
DR   SMR; Q92506; -.
DR   BioGrid; 113653; 16.
DR   IntAct; Q92506; 3.
DR   STRING; 9606.ENSP00000363794; -.
DR   DrugBank; DB03461; 2'-Monophosphoadenosine 5'-Diphosphoribose.
DR   DrugBank; DB00157; NADH.
DR   SwissLipids; SLP:000001271; -.
DR   iPTMnet; Q92506; -.
DR   PhosphoSitePlus; Q92506; -.
DR   BioMuta; HSD17B8; -.
DR   DMDM; 12643402; -.
DR   EPD; Q92506; -.
DR   MaxQB; Q92506; -.
DR   PaxDb; Q92506; -.
DR   PeptideAtlas; Q92506; -.
DR   PRIDE; Q92506; -.
DR   TopDownProteomics; Q92506; -.
DR   DNASU; 7923; -.
DR   Ensembl; ENST00000230236; ENSP00000230236; ENSG00000112474.
DR   Ensembl; ENST00000374662; ENSP00000363794; ENSG00000204228.
DR   Ensembl; ENST00000414463; ENSP00000387753; ENSG00000228357.
DR   Ensembl; ENST00000422433; ENSP00000406488; ENSG00000232357.
DR   Ensembl; ENST00000427295; ENSP00000403538; ENSG00000228712.
DR   Ensembl; ENST00000454191; ENSP00000413950; ENSG00000225312.
DR   GeneID; 7923; -.
DR   KEGG; hsa:7923; -.
DR   UCSC; uc003odi.3; human.
DR   CTD; 7923; -.
DR   DisGeNET; 7923; -.
DR   GeneCards; HSD17B8; -.
DR   HGNC; HGNC:3554; HSD17B8.
DR   HPA; HPA042132; -.
DR   MIM; 601417; gene.
DR   neXtProt; NX_Q92506; -.
DR   OpenTargets; ENSG00000204228; -.
DR   PharmGKB; PA29484; -.
DR   eggNOG; KOG1200; Eukaryota.
DR   eggNOG; COG1028; LUCA.
DR   GeneTree; ENSGT00760000118868; -.
DR   HOVERGEN; HBG002145; -.
DR   InParanoid; Q92506; -.
DR   KO; K13370; -.
DR   OMA; HMSEEDW; -.
DR   OrthoDB; EOG09370VMU; -.
DR   PhylomeDB; Q92506; -.
DR   TreeFam; TF313099; -.
DR   Reactome; R-HSA-535734; Fatty acid, triacylglycerol, and ketone body metabolism.
DR   SABIO-RK; Q92506; -.
DR   UniPathway; UPA00094; -.
DR   UniPathway; UPA00769; -.
DR   ChiTaRS; HSD17B8; human.
DR   EvolutionaryTrace; Q92506; -.
DR   GeneWiki; HSD17B8; -.
DR   GenomeRNAi; 7923; -.
DR   PRO; PR:Q92506; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000112474; -.
DR   CleanEx; HS_HSD17B8; -.
DR   Genevisible; Q92506; HS.
DR   GO; GO:0005740; C:mitochondrial envelope; IEA:Ensembl.
DR   GO; GO:0005759; C:mitochondrial matrix; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0003857; F:3-hydroxyacyl-CoA dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0047025; F:3-oxoacyl-[acyl-carrier-protein] reductase (NADH) activity; IMP:UniProtKB.
DR   GO; GO:0004303; F:estradiol 17-beta-dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0070404; F:NADH binding; IDA:UniProtKB.
DR   GO; GO:0047035; F:testosterone dehydrogenase (NAD+) activity; IEA:UniProtKB-EC.
DR   GO; GO:0008209; P:androgen metabolic process; IEA:Ensembl.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0006703; P:estrogen biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:UniProtKB.
DR   GO; GO:0051290; P:protein heterotetramerization; IDA:UniProtKB.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   InterPro; IPR020904; Sc_DH/Rdtase_CS.
DR   InterPro; IPR002347; SDR_fam.
DR   PRINTS; PR00081; GDHRDH.
DR   PRINTS; PR00080; SDRFAMILY.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   PROSITE; PS00061; ADH_SHORT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Lipid biosynthesis; Lipid metabolism;
KW   Mitochondrion; NAD; Oxidoreductase; Phosphoprotein; Polymorphism;
KW   Reference proteome; Steroid biosynthesis.
FT   CHAIN         1    261       Estradiol 17-beta-dehydrogenase 8.
FT                                /FTId=PRO_0000054598.
FT   NP_BIND      15     23       NAD. {ECO:0000244|PDB:2PD6,
FT                                ECO:0000244|PDB:4CQL,
FT                                ECO:0000269|PubMed:25203508,
FT                                ECO:0000269|Ref.11}.
FT   NP_BIND      42     43       NAD. {ECO:0000244|PDB:2PD6,
FT                                ECO:0000244|PDB:4CQL,
FT                                ECO:0000269|PubMed:25203508,
FT                                ECO:0000269|Ref.11}.
FT   NP_BIND      74     76       NAD. {ECO:0000244|PDB:2PD6,
FT                                ECO:0000244|PDB:4CQL,
FT                                ECO:0000269|PubMed:25203508,
FT                                ECO:0000269|Ref.11}.
FT   NP_BIND     169    173       NAD. {ECO:0000244|PDB:2PD6,
FT                                ECO:0000244|PDB:4CQL,
FT                                ECO:0000269|PubMed:25203508,
FT                                ECO:0000269|Ref.11}.
FT   NP_BIND     202    204       NAD. {ECO:0000244|PDB:2PD6,
FT                                ECO:0000244|PDB:4CQM,
FT                                ECO:0000269|Ref.11}.
FT   ACT_SITE    169    169       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10001}.
FT   BINDING     156    156       Substrate. {ECO:0000250}.
FT   MOD_RES      60     60       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P50171}.
FT   MOD_RES     160    160       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P50171}.
FT   MOD_RES     173    173       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P50171}.
FT   VARIANT     158    158       V -> L (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035844.
FT   VARIANT     190    190       H -> R (in dbSNP:rs34491699).
FT                                /FTId=VAR_052316.
FT   MUTAGEN      42     42       D->A: Reduced NADH-dependent reductase
FT                                activity with acetoacetyl-CoA. Reduced
FT                                NADH-dependent reductase activity with
FT                                9,10-phenanthrene quinone. Increases
FT                                NADPH-dependent reductase activitites. No
FT                                effect on the ability to restore growth
FT                                of an OAR1-deficient yeast mutant.
FT                                {ECO:0000269|PubMed:25203508}.
FT   MUTAGEN     148    148       R->E: No effect on the ability to restore
FT                                growth of an OAR1-deficient yeast mutant.
FT                                {ECO:0000269|PubMed:25203508}.
FT   MUTAGEN     169    169       Y->A: Strongly reduced NADH-dependent
FT                                reductase activity with acetoacetyl-CoA.
FT                                Strongly reduced NADH-dependent reductase
FT                                activity with 9,10-phenanthrene quinone.
FT                                Decreases NADPH-dependent reductase
FT                                activitity with acetoacetyl-CoA, but
FT                                increases NADPH-dependent reductase
FT                                activitity with 9,10-phenanthrene
FT                                quinone. No effect on the ability to
FT                                restore growth of an OAR1-deficient yeast
FT                                mutant. {ECO:0000269|PubMed:25203508}.
FT   MUTAGEN     173    173       K->A: Abolishes NADH-dependent reductase
FT                                activity with acetoacetyl-CoA. Strongly
FT                                reduced NADH-dependent reductase activity
FT                                with 9,10-phenanthrene quinone. Slightly
FT                                decreases NADPH-dependent reductase
FT                                activitity with acetoacetyl-CoA, but
FT                                increases NADPH-dependent reductase
FT                                activitity with 9,10-phenanthrene
FT                                quinone. No effect on the ability to
FT                                restore growth of an OAR1-deficient yeast
FT                                mutant. {ECO:0000269|PubMed:25203508}.
FT   MUTAGEN     189    189       R->E: No effect on the ability to restore
FT                                growth of an OAR1-deficient yeast mutant.
FT                                {ECO:0000269|PubMed:25203508}.
FT   CONFLICT    117    117       E -> R (in Ref. 5; BAA11529).
FT                                {ECO:0000305}.
FT   CONFLICT    193    193       R -> P (in Ref. 5; BAA11529).
FT                                {ECO:0000305}.
FT   CONFLICT    208    208       Q -> K (in Ref. 5; BAA11529).
FT                                {ECO:0000305}.
FT   CONFLICT    212    212       Q -> K (in Ref. 5; BAA11529).
FT                                {ECO:0000305}.
FT   TURN          8     11       {ECO:0000244|PDB:4CQM}.
FT   STRAND       13     17       {ECO:0000244|PDB:2PD6}.
FT   TURN         18     20       {ECO:0000244|PDB:2PD6}.
FT   HELIX        22     33       {ECO:0000244|PDB:2PD6}.
FT   STRAND       37     44       {ECO:0000244|PDB:2PD6}.
FT   HELIX        45     53       {ECO:0000244|PDB:2PD6}.
FT   STRAND       70     73       {ECO:0000244|PDB:2PD6}.
FT   HELIX        79     93       {ECO:0000244|PDB:2PD6}.
FT   STRAND       98    102       {ECO:0000244|PDB:2PD6}.
FT   HELIX       112    114       {ECO:0000244|PDB:2PD6}.
FT   HELIX       117    127       {ECO:0000244|PDB:2PD6}.
FT   HELIX       129    145       {ECO:0000244|PDB:2PD6}.
FT   STRAND      149    154       {ECO:0000244|PDB:2PD6}.
FT   HELIX       158    161       {ECO:0000244|PDB:2PD6}.
FT   HELIX       167    187       {ECO:0000244|PDB:2PD6}.
FT   HELIX       188    190       {ECO:0000244|PDB:2PD6}.
FT   STRAND      192    199       {ECO:0000244|PDB:2PD6}.
FT   STRAND      201    204       {ECO:0000244|PDB:4CQM}.
FT   TURN        207    209       {ECO:0000244|PDB:2PD6}.
FT   HELIX       212    216       {ECO:0000244|PDB:2PD6}.
FT   HELIX       219    221       {ECO:0000244|PDB:2PD6}.
FT   HELIX       230    241       {ECO:0000244|PDB:2PD6}.
FT   HELIX       243    245       {ECO:0000244|PDB:2PD6}.
FT   STRAND      252    256       {ECO:0000244|PDB:2PD6}.
FT   TURN        257    260       {ECO:0000244|PDB:4CQM}.
SQ   SEQUENCE   261 AA;  26974 MW;  8B8B2D7131714D71 CRC64;
     MASQLQNRLR SALALVTGAG SGIGRAVSVR LAGEGATVAA CDLDRAAAQE TVRLLGGPGS
     KEGPPRGNHA AFQADVSEAR AARCLLEQVQ ACFSRPPSVV VSCAGITQDE FLLHMSEDDW
     DKVIAVNLKG TFLVTQAAAQ ALVSNGCRGS IINISSIVGK VGNVGQTNYA ASKAGVIGLT
     QTAARELGRH GIRCNSVLPG FIATPMTQKV PQKVVDKITE MIPMGHLGDP EDVADVVAFL
     ASEDSGYITG TSVEVTGGLF M
//
